We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
Denmark - Medicaments Containing Insulin But Not Antibiotics - Market Analysis, Forecast, Size, Trends And Insights
Report Update: Feb 4, 2025

Denmark - Medicaments Containing Insulin But Not Antibiotics - Market Analysis, Forecast, Size, Trends And Insights

Single report
Sent by email within 24h (Mon-Fri)
What's the difference?
Subscription
Online access and download
from $350/month

Get instant access to more than 2 million reports, dashboards, and datasets on the IndexBox Platform.

View Pricing
Feb 4, 2025

Novo Nordisk Faces Investor Scrutiny Over CagriSema Trials

Novo Nordisk is currently navigating a challenging period, as investors demand more detailed information about its promising obesity drug candidate, CagriSema. According to a Reuters report, uncertainty surrounding trial results has negatively affected Novo's market performance, with shares taking a significant hit last December.

The pharmaceutical giant believes CagriSema, which combines semaglutide and cagrilintide, has the potential to outperform its existing weight-loss injection, Wegovy. However, investors are uncertain about its ability to compete with Eli Lilly's Mounjaro in the bustling obesity market. These concerns were exacerbated by weaker-than-expected trial results and notable side effects experienced by participants, such as nausea and fatigue, although weight loss was achieved.

In the December trial read-out, Novo reported that patients following the CagriSema treatment protocol lost an average of 22.7% body weight over 68 weeks, with 40.4% achieving over 25% weight loss. However, these results fell short of expectations, impacting Novo's market valuation by as much as $125 billion in a single day.

Despite the setback, the drug's capability to deliver significant weight loss coupled with potential mild to moderate side effects in line with other GLP-1 receptor agonists still holds promise. Reuters' interviews with trial participants highlight substantial weight loss alongside side effects like nausea and fatigue, indicating the drug's potential but with cautious optimism. IndexBox data shows that the global obesity management market is evolving rapidly, with major players like Novo and Eli Lilly vying for dominance through innovative pharmacological advancements.

Investor Reactions and Future Outlook

Investors and analysts have expressed a range of reactions to the trial data. Lukas Leu, representing healthcare-focused Bellevue Asset Management, voiced disappointment over Novo's delayed disclosure regarding the flexible dosing regime utilized during trials. The anticipation now builds towards Novo's forthcoming quarterly results release, where clarity around CagriSema's future is eagerly awaited.

Despite adverse reactions and data challenges, trial participants reported significant lifestyle changes. For instance, Michelle Rivera in the ongoing REDEFINE-4 trial noted a 22% reduction in body weight, marking the drug as transformative but also challenging due to persistent side effects. This highlights a pressing need to balance efficacy with tolerability in long-term obesity treatments.

As the competitive landscape intensifies, particularly against Eli Lilly's strong presence, Novo Nordisk's strategic decisions and forthcoming trials will be pivotal. The company's ability to address investor concerns and optimize CagriSema's market readiness will shape its role in the burgeoning global obesity management market.

Source: IndexBox Market Intelligence Platform

This report provides an in-depth analysis of the medicaments containing insulin market in Denmark. Within it, you will discover the latest data on market trends and opportunities by country, consumption, production and price developments, as well as the global trade (imports and exports). The forecast exhibits the market prospects through 2030.

Product coverage:

  • Prodcom 21201230 - Medicaments containing insulin but not antibiotics, for therapeutic or prophylactic uses, not put up in measured doses or for retail sale

Country coverage:

  • Denmark

Data coverage:

  • Market volume and value
  • Per Capita consumption
  • Forecast of the market dynamics in the medium term
  • Trade (exports and imports) in Denmark
  • Export and import prices
  • Market trends, drivers and restraints
  • Key market players and their profiles

Reasons to buy this report:

  • Take advantage of the latest data
  • Find deeper insights into current market developments
  • Discover vital success factors affecting the market

This report is designed for manufacturers, distributors, importers, and wholesalers, as well as for investors, consultants and advisors.

In this report, you can find information that helps you to make informed decisions on the following issues:

  1. How to diversify your business and benefit from new market opportunities
  2. How to load your idle production capacity
  3. How to boost your sales on overseas markets
  4. How to increase your profit margins
  5. How to make your supply chain more sustainable
  6. How to reduce your production and supply chain costs
  7. How to outsource production to other countries
  8. How to prepare your business for global expansion

While doing this research, we combine the accumulated expertise of our analysts and the capabilities of artificial intelligence. The AI-based platform, developed by our data scientists, constitutes the key working tool for business analysts, empowering them to discover deep insights and ideas from the marketing data.

  1. 1. INTRODUCTION

    Making Data-Driven Decisions to Grow Your Business

    1. REPORT DESCRIPTION
    2. RESEARCH METHODOLOGY AND AI PLATFORM
    3. DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
    4. GLOSSARY AND SPECIFIC TERMS

  2. 2. EXECUTIVE SUMMARY

    A Quick Overview of Market Performance

    1. KEY FINDINGS
    2. MARKET TRENDS This Chapter is Available Only for the Professional Edition PRO

  3. 3. MARKET OVERVIEW

    Understanding the Current State of The Market and Its Prospects

    1. MARKET SIZE
    2. MARKET STRUCTURE
    3. TRADE BALANCE
    4. PER CAPITA CONSUMPTION
    5. MARKET FORECAST TO 2030

  4. 4. MOST PROMISING PRODUCT

    Finding New Products to Diversify Your Business

    This Chapter is Available Only for the Professional Edition PRO
    1. TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
    2. BEST-SELLING PRODUCTS
    3. MOST CONSUMED PRODUCT
    4. MOST TRADED PRODUCT
    5. MOST PROFITABLE PRODUCT FOR EXPORT

  5. 5. MOST PROMISING SUPPLYING COUNTRIES

    Choosing the Best Countries to Establish Your Sustainable Supply Chain

    This Chapter is Available Only for the Professional Edition PRO
    1. TOP COUNTRIES TO SOURCE YOUR PRODUCT
    2. TOP PRODUCING COUNTRIES
    3. TOP EXPORTING COUNTRIES
    4. LOW-COST EXPORTING COUNTRIES

  6. 6. MOST PROMISING OVERSEAS MARKETS

    Choosing the Best Countries to Boost Your Exports

    This Chapter is Available Only for the Professional Edition PRO
    1. TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
    2. TOP CONSUMING MARKETS
    3. UNSATURATED MARKETS
    4. TOP IMPORTING MARKETS
    5. MOST PROFITABLE MARKETS

  7. 7. PRODUCTION

    The Latest Trends and Insights into The Industry

    1. PRODUCTION VOLUME AND VALUE

  8. 8. IMPORTS

    The Largest Import Supplying Countries

    1. IMPORTS FROM 2012–2024
    2. IMPORTS BY COUNTRY
    3. IMPORT PRICES BY COUNTRY

  9. 9. EXPORTS

    The Largest Destinations for Exports

    1. EXPORTS FROM 2012–2024
    2. EXPORTS BY COUNTRY
    3. EXPORT PRICES BY COUNTRY

  10. 10. PROFILES OF MAJOR PRODUCERS

    The Largest Producers on The Market and Their Profiles

    This Chapter is Available Only for the Professional Edition PRO

  11. LIST OF TABLES

    1. Key Findings In 2024
    2. Market Volume, In Physical Terms, 2012–2024
    3. Market Value, 2012–2024
    4. Per Capita Consumption In 2012-2024
    5. Imports, In Physical Terms, By Country, 2012–2024
    6. Imports, In Value Terms, By Country, 2012–2024
    7. Import Prices, By Country Of Origin, 2012–2024
    8. Exports, In Physical Terms, By Country, 2012–2024
    9. Exports, In Value Terms, By Country, 2012–2024
    10. Export Prices, By Country Of Destination, 2012–2024

  12. LIST OF FIGURES

    1. Market Volume, In Physical Terms, 2012–2024
    2. Market Value, 2012–2024
    3. Market Structure – Domestic Supply vs. Imports, In Physical Terms, 2012-2024
    4. Market Structure – Domestic Supply vs. Imports, In Value Terms, 2012-2024
    5. Trade Balance, In Physical Terms, 2012-2024
    6. Trade Balance, In Value Terms, 2012-2024
    7. Per Capita Consumption, 2012-2024
    8. Market Volume Forecast to 2030
    9. Market Value Forecast to 2030
    10. Products: Market Size And Growth, By Type
    11. Products: Average Per Capita Consumption, By Type
    12. Products: Exports And Growth, By Type
    13. Products: Export Prices And Growth, By Type
    14. Production Volume And Growth
    15. Exports And Growth
    16. Export Prices And Growth
    17. Market Size And Growth
    18. Per Capita Consumption
    19. Imports And Growth
    20. Import Prices
    21. Production, In Physical Terms, 2012–2024
    22. Production, In Value Terms, 2012–2024
    23. Imports, In Physical Terms, 2012–2024
    24. Imports, In Value Terms, 2012–2024
    25. Imports, In Physical Terms, By Country, 2024
    26. Imports, In Physical Terms, By Country, 2012–2024
    27. Imports, In Value Terms, By Country, 2012–2024
    28. Import Prices, By Country Of Origin, 2012–2024
    29. Exports, In Physical Terms, 2012–2024
    30. Exports, In Value Terms, 2012–2024
    31. Exports, In Physical Terms, By Country, 2024
    32. Exports, In Physical Terms, By Country, 2012–2024
    33. Exports, In Value Terms, By Country, 2012–2024
    34. Export Prices, By Country Of Destination, 2012–2024

Recommended posts

Free Data: Medicaments Containing Insulin But Not Antibiotics - Denmark
Table
Medicaments Containing Insulin But Not Antibiotics - Denmark - Table
Dashboard
Medicaments Containing Insulin But Not Antibiotics - Denmark - Dashboard
Report
Medicaments Containing Insulin But Not Antibiotics - Denmark - Report